2138442-31-4

2138442-31-4 structure

Name: Plamotamab
Chemical Name: Plamotamab
CAS Number: 2138442-31-4
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2023-03-10 00:08:57
Modify Date: 2024-04-06 11:23:47
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and resultes in tumor regression in vivo[1][2].

Name	Plamotamab

Description	Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and resultes in tumor regression in vivo[1][2].
Related Catalog	Research Areas >> Cancer
In Vitro	Plamotamab 在体外诱导人 PBMC 内源性 B 细胞的杀伤和内源性 CD8+ T 细胞的激活，EC50 值为 0.113 nM[2]。 Plamotamab 在体外诱导 T 细胞介导的对 Raji 肿瘤细胞的杀伤，EC50 值为 0.144 nM[2]。 Plamotamab 结合 CD3δ/ε、CD3+ T 细胞、CD4+ T 细胞、CD8+ T 细胞、B 细胞、Raji 细胞，EC50 分别为 2.1 nM、11.78 nM、10.12 nM、200.3 nM 和 134.8 nM[2]。
In Vivo	Plamotamab (0.17 mg/kg；腹腔注射) 在含有 Raji 异种移植物的人 PBMC 移植小鼠模型中引起肿瘤生长抑制[2]。 Plamotamab (0.3 mg/kg；腹腔注射) 导致食蟹猴中细胞因子释放，安全性有待提高[2]。
References	[1]. Parrondo RD, et al. Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742. [2]. Luo Peter PZ, et al. Anti-CD3 antibodies and methods of use thereof. World Intellectual Property Organization, WO2022170740 A1. 2022-08-18.

No Any Chemical & Physical Properties